Dementia in the oldest old: a multi-factorial and growing public health issue
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The population of oldest old, or people aged 85 and older, is growing rapidly. A better understanding of dementia in this population is thus of increasing national and global importance. In this review, we describe the major epidemiological studies, prevalence, clinical presentation, neuropathological and imaging features, risk factors, and treatment of dementia in the oldest old. Prevalence estimates for dementia among those aged 85+ ranges from 18 to 38%. The most common clinical syndromes are Alzheimer's dementia, vascular dementia, and mixed dementia from multiple etiologies. The rate of progression appears to be slower than in the younger old. Single neuropathological entities such as Alzheimer's dementia and Lewy body pathology appear to have declining relevance to cognitive decline, while mixed pathology with Alzheimer's disease, vascular disease (especially cortical microinfarcts), and hippocampal sclerosis appear to have increasing relevance. Neuroimaging data are sparse. Risk factors for dementia in the oldest old include a low level of education, poor mid-life general health, low level of physical activity, depression, and delirium, whereas apolipoprotein E genotype, late-life hypertension, hyperlipidemia, and elevated peripheral inflammatory markers appear to have less relevance. Treatment approaches require further study, but the oldest old may be more prone to negative side effects compared with younger patients and targeted therapies may be less efficacious since single pathologies are less frequent. We also highlight the limitations and challenges of research in this area, including the difficulty of defining functional decline, a necessary component for a dementia diagnosis, the lack of normative neuropsychological data, and other shortcomings inherent in existing diagnostic criteria. In summary, our understanding of dementia in the oldest old has advanced dramatically in recent years, but more research is needed, particularly among varied racial, ethnic, and socioeconomic groups, and with respect to biomarkers such as neuroimaging, modifiable risk factors, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“Furthermore, despite the fact that the oldest old repre sent the largest and fastest growing population with dementia [7], the majority of dementia research focuses on the younger old.”
A Prospective Study of Physical Activity and Cognitive Decline in Elderly Women: Women Who Walk
Yaffe, K., Barnes, D., Nevitt, M., Lui, L.-Y., & Covinsky, K. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.14.1703 · Cited by 921
Self-citationAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
McKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Fratiglioni, L., Viitanen, M., von Strauss, E., Tontodonati, V., Herlitz, A., & Winblad, B. (1997) · Neurology · doi:10.1212/wnl.48.1.132 · Cited by 556
Dementia incidence continues to increase with age in the oldest old: The 90+ study
Corrada, M. M., Brookmeyer, R., Paganini‐Hill, A., Berlau, D., & Kawas, C. H. (2010) · Annals of Neurology · doi:10.1002/ana.21915 · Cited by 523 · cited 3×
“old women, a factor that is associated with higher rates of dementia [22,30].”
Total cholesterol and risk of mortality in the oldest old
Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knock, D. L., Meinders, A. E., & Westendorp, R. G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04430-9 · Cited by 474
Systemic markers of inflammation and cognitive decline in old age
Schram, M. T., Euser, S. M., De Craen, A. J. M., Witteman, J. C., Frölich, M., Hofman, A., Jolles, J., Breteler, M. M. B., & Westendorp, R. G. J. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01159.x · Cited by 326 · cited 1×
“Similarly, the Vantaa 85+ Study reported only a weak association between cognitive decline and infl ammatory markers among nondemented oldest old enrollees [80].”
Bayesian probabilistic population projections for all countries
Raftery, A. E., Li, N., Ševčíková, H., Gerland, P., & Heilig, G. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211452109 · Cited by 298 · cited 1×
“5 by 2050, and similar declines are expected in most countries worldwide [5].”
Hippocampal sclerosis in advanced age: clinical and pathological features
Nelson, P. T., Schmitt, F. A., Lin, Y., Abner, E. L., Jicha, G. A., Patel, E., Thomason, P. C., Neltner, J. H., Smith, C. D., Santacruz, K. S., et al. (2011) · Brain · doi:10.1093/brain/awr053 · Cited by 279
The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old
Barkhof, F., Polvikoski, T. M., van Straaten, E. C. W., Kalaria, R. N., Sulkava, R., Aronen, H. J., Niinistö, L., Rastas, S., Oinas, M., Scheltens, P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277459.83543.99 · Cited by 204
Dementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old
James, B. D. (2012) · JAMA · doi:10.1001/jama.2012.3556 · Cited by 199 · cited 1×
“Furthermore, co-existing pathologies appear to increase risk for dementia, with proportionally greater numbers of oldest old patients with mixed pathology demonstrating dementia compared with the oldest old with single pathologies [52].”
White, L. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1178 · Cited by 193
Role of the neuropathology of Alzheimer disease in dementia in the oldest-old
Haroutunian, V., Schnaider-Beeri, M., Schmeidler, J., Wysocki, M., Purohit, D. P., Perl, D. P., Libow, L. S., Lesser, G. T., Maroukian, M., & Grossman, H. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.9.1211 · Cited by 154
APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old
Juva, K., Verkkoniemi, A., Viramo, P., Polvikoski, T., Kainulainen, K., Kontula, K., & Sulkava, R. (2000) · Neurology · doi:10.1212/wnl.54.2.412 · Cited by 108
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T., & Satlin, A. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-57 · Cited by 95 · cited 1×
“For example, one study recently reported on the safety and tolerability of donepezil at 10 mg versus 23 mg dose in a large cohort of older patients with dementia, including 116 patients aged 85 to 90 years [83].”
Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old
Polvikoski, T. M., van Straaten, E. C. W., Barkhof, F., Sulkava, R., Aronen, H. J., Niinistö, L., Oinas, M., Scheltens, P., Erkinjuntti, T., & Kalaria, R. N. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d6f9 · Cited by 88
Microvascular Burden and Alzheimer-Type Lesions Across the Age Spectrum
Costanza, A., Xekardaki, A., Kövari, E., Gold, G., Bouras, C., & Giannakopoulos, P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120835 · Cited by 36 · cited 1×
“Cerebrovascular pathology appears to correlate well with cognition across all ages, even among the oldest old [48].”
Depressive Symptoms and Cognitive Decline in Nondemented Elderly Women: A Prospective Study
Yaffe, K., Blackwell, T., Gore, R., Sands, L., Reus, V., & Browner, W. S. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.425 · Cited by 8
Self-citation
Cited by
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Incidence of Parkinson disease in North America
Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., on behalf of the Parkinson’s Foundation P4 Group, et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00410-y · Cited by 341
“Symptomatic cognitive dysfunction or dementia, due to Alzheimer disease, vascular dementia, toxic or metabolic cognitive dysfunction, increases with age 52 and becomes very prevalent in the 8 th decade and beyond 12,53,54 .”
Corriveau, R. A., Bosetti, F., Emr, M., Gladman, J. T., Koenig, J. I., Moy, C. S., Pahigiannis, K., Waddy, S. P., & Koroshetz, W. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0334-7 · Cited by 240
APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction
Soto, I., Graham, L. C., Richter, H. J., Simeone, S. N., Radell, J. E., Grabowska, W., Funkhouser, W. K., Howell, M. C., & Howell, G. R. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002279 · Cited by 140
Neuropathological and transcriptomic characteristics of the aged brain
Miller, J. A., Guillozet-Bongaarts, A., Gibbons, L. E., Postupna, N., Renz, A., Beller, A. E., Sunkin, S. M., Ng, L., Rose, S. E., Smith, K. A., et al. (2017) · eLife · doi:10.7554/elife.31126 · Cited by 134
Metadata
- Authors
- Gardner, R. C., Valcour, V., & Yaffe, K.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013
- Volume
- 5
- Issue
- 4
- Pages
- 27
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2160141785
- Cited by
- 108
- References
- 20
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.